Clinical trials: Neoplasms, Breast
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01215123
- Testing
- Bevacizumab
- Where
- 12 sites in Argentina
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
- Trial name
- NCT00213980
- Testing
- Zoledronate
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, HER2-negative Breast Cancer
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
This phase II is studying the side effects and how well carboplatin and paclitaxel albumin-stabilized nanoparticle formulation when together with bevacizumab or trastuzumab before surgery works in treating patients with stage…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00618657
- Testing
- Carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of California, Irvine
Breast Cancer, Skin Reactions Secondary to Radiation Therapy
Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy.
- Trial name
- NCT02203565
- Testing
- Dakin's solution, radiation therapy, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Kita-kyushu Lung Cancer Antigen 1, Human
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Background: Researchers have found a new way to treat cancer using T cell therapy. The therapy used in this study is T Cell Receptor (TCR) Gene Therapy Targeting Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer germline…
- Trial name
- NCT05035407
- Testing
- IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasm, Physical Activity
Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
The investigators seek to conduct a home based exercise intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy.
- Trial name
- WISER-NET (NCT03280836)
- Testing
- Exercise
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions
This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular…
- Trial name
- NCT03070236
- Testing
- Survey
- Where
- 6 sites in United States
- Volunteers
- 912 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Invasive Breast Carcinoma
Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
This clinical trial studies the feasibility of implementing various adaptive training exercise programs to improve cardiorespiratory fitness in patients after receiving breast cancer treatment.
- Trial name
- ACTIVATE (NCT04667481)
- Testing
- Aerobic Exercise Intervention, Resistance Exercise Intervention, Exercise Intervention: Digital copies and outline of sessions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Risk Reduction, Mammographic Density Reduction
Low Dose Tamoxifen for Mammographic Density Reduction
KARISMA2 is a randomized, double-blinded, six-armed placebo controlled study to identify a low dose of tamoxifen, with less side-effects and a density reduction non-inferior to the standard dose of 20 mg.
- Trial name
- KARISMA2 (NCT03346200)
- Testing
- Tamoxifen Oral Tablet
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- Per Hall
Breast Carcinoma, Estrogen Receptor Positive
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
- Trial name
- NCT03831711
- Testing
- Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrei Iagaru
Breast Cancer
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290732
- Testing
- Intraductal arm, Intravenous arm
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
All patients (with Stages 0-II breast cancer) will receive an accelerated three week regimen of prone whole breast radiotherapy.
- Trial name
- NCT01000662
- Testing
- Daily Radiation Therapy, Weekly Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 412 people
- Sponsor
- NYU Langone Health
Breast Cancer
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: Cabozantinib (XL184) Nivolumab
- Trial name
- NCT03316586
- Testing
- Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Fatigue
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl (Concerta) can help to control fatigue in patients with breast, gastrointestinal, lymphoma, myeloma or lung cancer who are going through…
- Conditions
- Breast Cancer, Fatigue, Gastrointestinal Cancer
- Trial name
- NCT00516269
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IIA Breast Cancer, Stage IIB Breast Cancer
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
This pilot clinical trial studies chemotherapy before surgery and tissue sample collection in patients with stage IIA-IIIC breast cancer.
- Conditions
- Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01897441
- Testing
- Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer
The purpose of this study is to evaluate the use of a device that helps coordinate the breathing cycle in the radiation treatment of the breast in order to minimize the radiation dose to the normal structures around the breast.
- Trial name
- NCT00328783
- Testing
- Active Breathing Coordinator (ABC), Radiation Therapy
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastases, Brain
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
- Trial name
- NCT00820222
- Testing
- capecitabine, lapatinib, trastuzumab
- Where
- 164 sites in United States, Belgium and 12 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
The purpose of this study is to look at the amount of cancer cells in the blood of participants who are being treated with denosumab.
- Conditions
- Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT03070002
- Testing
- Denosumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Metastatic Breast Cancer
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor…
- Trial name
- NCT05361655
- Testing
- Palbociclib + an aromatase inhibitor, Aromatase inhibitor
- Where
- United States
- Volunteers
- 2,888 people
- Sponsor
- Pfizer
Hormone-sensitive Metastatic Breast Cancer
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers.
- Trial name
- NCT01205685
- Testing
- OSI-906, Erlotinib, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.